Cargando…

Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study

Patients with inflammatory bowel disease (IBD) often have associated conditions, for which anti-inflammatory medication with cyclo-oxygenase (COX) inhibitors may be helpful. The current evidence is conflicting regarding the role of COX-inhibitors in causing relapse in IBD. This case-control study ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hensley, Abigail, Beales, Ian L. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588181/ https://www.ncbi.nlm.nih.gov/pubmed/26371009 http://dx.doi.org/10.3390/ph8030512

Ejemplares similares

Cyclooxygenase-1-selective inhibitor SC-560
por: Long, Sihui, et al.
Publicado: (2009)

Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?
por: Khan, Shanzana, et al.
Publicado: (2019)

Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk
por: Moore, R Andrew, et al.
Publicado: (2007)

Factors associated with the use of probiotics in patients with inflammatory bowel disease
por: Agathou, Claire Louise, et al.
Publicado: (2013)

Comparative QSAR analysis of cyclo-oxygenase2 inhibiting drugs
por: Mohanapriya, Arumugam, et al.
Publicado: (2012)

Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage
por: Mirabito Colafella, Katrina M., et al.
Publicado: (2022)

Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
por: Rama, Tiago Azenha, et al.
Publicado: (2022)

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells
por: Basu, Gargi D, et al.
Publicado: (2005)

Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor
por: Fisher, Jason C, et al.
Publicado: (2011)

The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor
por: Lau, C. S., et al.
Publicado: (1992)

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis
por: Geusens, Piet, et al.
Publicado: (2008)

Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer
por: Connolly, E M, et al.
Publicado: (2002)

Specific desensitization of the canine renal vasculature to angiotensin II despite cyclo-oxygenase inhibition.
por: Meggs, L. G., et al.
Publicado: (1985)

Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity
por: Jones, D J L, et al.
Publicado: (2004)

Cyclo‐oxygenase selectivity and chemical groups of nonsteroidal anti‐inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase
por: Bakhriansyah, Mohammad, et al.
Publicado: (2019)

The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases
por: Galgut, Bianca J., et al.
Publicado: (2018)

Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes
por: Moore, R Andrew, et al.
Publicado: (2008)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer
por: Leung, W K, et al.
Publicado: (2001)

The association between cyclo-oxygenase-2 expression and cell proliferation and angiogenesis in human breast cancer
por: Kirkpatrick, K, et al.
Publicado: (2001)

Cyclo-Oxygenase 2 Modulates Chemoresistance in Breast Cancer Cells Involving NF-κB
por: Zatelli, Maria Chiara, et al.
Publicado: (2009)

The Anti-Inflammatory Effects of Lipoxygenase and Cyclo-Oxygenase Inhibitors in Inflammation-Induced Human Fetal Glia Cells and the Aβ Degradation Capacity of Human Fetal Astrocytes in an Ex vivo Assay
por: Pihlaja, Rea, et al.
Publicado: (2017)

Pro-Inflammatory Diet Is Correlated with High Veillonella rogosae, Gut Inflammation and Clinical Relapse of Inflammatory Bowel Disease
por: da Rocha, Ilanna Marques Gomes, et al.
Publicado: (2023)

Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: Lefevre, Pavine L C, et al.
Publicado: (2020)

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells.
por: Tjandrawinata, R. R., et al.
Publicado: (1997)

The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall
por: de Jongh, R, et al.
Publicado: (2009)

Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK
por: Cummings, JR Fraser, et al.
Publicado: (2021)

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]
por: Wittenberg, Ralf H, et al.
Publicado: (2006)

Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
por: Li, Mengtao, et al.
Publicado: (2020)

Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK
por: Aksan, Aysegül, et al.
Publicado: (2021)

Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease
por: Kittanakom, Saranya, et al.
Publicado: (2017)

Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases
por: Axelrad, Jordan E., et al.
Publicado: (2019)

Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease
por: Liu, Fang, et al.
Publicado: (2020)

Pancreatitis-Associated Protein Does Not Predict Disease Relapse in Inflammatory Bowel Disease Patients
por: Nunes, Tiago, et al.
Publicado: (2014)

Cyclo-oxygenase 2, a putative mediator of vessel remodeling, is expressed in the brain AVM vessels and associates with inflammation
por: Keränen, Sara, et al.
Publicado: (2021)

Heme Oxygenase-1: Its Therapeutic Roles in Inflammatory Diseases
por: Pae, Hyun-Ock, et al.
Publicado: (2009)

Correction: Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
Publicado: (2020)

Protective Effects of Long-Term Usage of Cyclo-Oxygenase-2 Inhibitors on Colorectal Cancer in Genetically Predisposed Individuals and Their Overall Effect on Prognosis: A Systematic Review
por: Narayana, Sri Harsha, et al.
Publicado: (2023)

Dysbiosis and relapse-related microbiome in inflammatory bowel disease: A shotgun metagenomic approach
por: Serrano-Gómez, Gerard, et al.
Publicado: (2021)

Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study
por: Mastbergen, Simon C, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_m3dmrskd99m80rc7vgsgctbskg